An observational study in Early Clinical Deterioration and Early Warning Score, sponsored by Erzincan University. Status unknown at 1 site in Turkey. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-07-17.
Sponsored by Erzincan University · Observational
The VitalPac Early Warning Score (VIEWS) scoring system, developed by Prytherch et al., Is an early warning system that aims to predict the first 24-hour mortality in emergency patients.
National early warning score (NEWS) is another early warning scoring system recommended by the Royal College of Physicians in London to detect early clinical deterioration in hospitalized patients.
The aim of this study was to determine the early clinical deterioration after ICU and hence the rate of admission to intensive care and to evaluate whether these two scoring systems can be used to determine early clinical deterioration in intensive care early discharge.
48 studies on the registry are indexed under Clinical Deterioration; 14 are open to participants now.
This study's planned enrollment of 390 is close to the median of 395 across 24 observational studies indexed under Clinical Deterioration.
Browse Clinical Deterioration studies →Erzincan University is the lead sponsor of 42 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
390 patients who were discharged from the intensive care unit over the age of 18 and who were taken back within 24 hours will be included.
Exclusion Criteria:
National early warning score (NEWS) is another early warning scoring system recommended by the Royal College of Physicians in London to detect early clinical deterioration in hospitalized patients
Number of patients recovered due to early clinical deterioration within the first 24 hours after ICU discharge
The aim of this study is to determine the early clinical deterioration in the first 24 hours after ICU discharge and therefore the rate of admission to ICU.
Time frame: six month
Plan to share: No
This study is status unknown, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Erzincan University